| 摘要 |
A method of recovering urokinase, also known as the plasminogen activator in urine or the fibrinolytic activator in urine, from human urine comprises contacting an impure solution of urokinase, obtained by eluting an adsorbate derived from passing urine through an adsorbent with a synthetic cation-exchange resin, e.g. "Amberlite (Registered Trade Mark) IRC 50 XE-97," and eluting said resin with an aqueous solution of an electrolyte having a pH that will cause the eluate to have a pH between 5 and 11. The first adsorption process using human urine is conveniently carried out by adjusting the pH of the urine to between 3 and 8, e.g. with sodium hydroxide solution, and contacting this with silica gel or a cation-exchanging silicate, e.g. the water-containing sodium aluminium silicates, then eluting with an aqueous solution, e.g. of ammonia, having a pH such that the eluate has a pH of between 9 and 11.5. This eluate is either freeze-dried and the resulting impure urokinase redissolved or the urokinase is precipitated with sodium chloride or ammonium sulphate solutions or with ethanol, acetone or dioxan, then redissolved and this solution is then contacted with the synthetic cation-exchange resin which has been equilibrated with an aqueous solution, e.g. of disodium phosphate, monosodium phosphate, and sodium chloride, that has a pH between 5 and 7.5 and a cation strength between 0.1 and 1 gram equivalents per litre. The resin was then eluted with a 0.5 molar solution of sodium chloride and the fractions containing most urokinase combined then freeze-dried to produce urokinase in solid form. As alternatives to silica gel in the first adsorption process, barium sulphate, calcium phosphate or oxycellulose may be used.
|
